In what has become one of the most publicized legal disputes in the tech world, Elon Musk is taking a stand against OpenAI, the company he co-founded. His latest legal maneuver, filed for a preliminary injunction against OpenAI’s transition to a fully for-profit entity, ignites further controversy in the rapidly evolving field of artificial intelligence.
Profit-driven
In a recent interview, CEO Vas Narasimhan shared a bullish forecast for Novartis, projecting a consistent annual growth rate of at least 5% through 2028. This outlook aims to assuage fears that often accompany the expiration of patents on the company’s blockbuster drugs, particularly given the industry‘s historical precedent of declining revenues when key patents
OpenAI, the trailblazing artificial intelligence company, is on the verge of securing a massive $6.5 billion funding round that could redefine its corporate structure and operational strategies. According to inside sources, this financing is likely to be issued in the form of convertible notes, a decision that significantly signals the company’s growing need for capital
The recent ruling by U.S. District Judge Zahid Quraishi in Trenton, New Jersey, to uphold the law requiring drug manufacturers like Bristol Myers Squibb and Johnson & Johnson to negotiate prices of their blood clot prevention drugs with the U.S government’s Medicare program has sparked controversy in the pharmaceutical industry. Despite the drug companies’ arguments
Unlock the profit potential of online courses with our strategies. Learn how to choose a profitable topic, create engaging content, set the right price, market effectively, engage participants, optimize course delivery, implement upselling strategies, and build a strong online presence.